or
Bookmark and Share
Treatment of hepatitis C using hyperthermia
   
Document Number
US Patent 6347633
Issued Date
February 19, 2002
Link
Inventors
Map
Abstract
The invention provides a method of treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce or eliminate the patient's viral load of HCV.
Drawing
Treatment of hepatitis C using hyperthermia - US Patent 6347633 Drawing
Drawing from US Patent 6347633
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
107
Comments:
no comments yet
Owner
First Circle Medical, Inc. (Minneapolis, MN)
Published
February 19, 2002
Application Number
09/484,360
Filed
January 14, 2000
US Classification
128/898  
Int'l Classification
A61F   7/12   (20060101)  
Assistant Examiner
Attorney/Law Firm
USPTO Field of Search
128/898  
Related Patents
6690975 - Methods for treating hepatitis C - Owned by Bistner Co., Ltd. (Tokyo,JP) Iryodenshiseiko Co., Ltd. (Osaka,JP) Yamamoto Vinita Co., Ltd. (Osaka,JP) Yamamoto; Itsuo (Osaka,JP) Nishide; Iwao (Osaka,JP) Yukawa; Susumu (Osaka,JP) Valentyna; Ostapenko (Osaka,JP)

While an interferon therapy is a conventional method for treating hepatitis C, no particular option exists currently in the treatment except for this interferon therapy. An object of the present invention is to provide a novel method for treating hepatitis C. The present invention includes a method for treating hepatitis C comprising warming a liver region of a human by sandwiching an upper abdominal region of a human body between electrodes on the front and back by supplying a high-frequency electric power to these electrodes.

6644320 - Treatment of hepatitis C using hyperthermia - Owned by First Circle Medical, Inc. (Minneapolis, MN)

The invention provides a method of treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce or eliminate the patient's viral load of HCV.

6951219 - Treatment of hepatitis C using hyperthermia - Owned by First Circle Medical, Inc. (Minneapolis, MN)

The invention provides a method of treating a patient infected with hepatitis C virus (HCV) comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce or eliminate the patient's viral load of HCV.

7074175 - Thermotherapy via targeted delivery of nanoscale magnetic particles

Disclosed are compositions comprising magnetic nanoparticles, a biocompatible coating, and a target-specific ligand. Also disclosed are devices for treating diseased tissue for use with such compositions. Further disclosed are methods for treating diseased tissue, such as cancer, using such compositions and devices, as well as methods for treating diseased tissue utilizing hypertermia.

6997863 - Thermotherapy via targeted delivery of nanoscale magnetic particles - Owned by Triton BioSystems, Inc. (Chelmsford, MA)

Disclosed are therapeutic methods for the treatment of disease material involving administration of a thermotherapeutic magnetic composition, which contains single-domain magnetic particles attached to a target-specific ligand, to a patient and application of an alternating magnetic field to inductively heat the thermotherapeutic magnetic composition. Also disclosed are methods of administering the thermotherapeutic magnetic material composition. The thermotherapeutic methods may be used where the predetermined target is associated with diseases, such as cancer, diseases of the immune system, and pathogen-borne diseases, and undesirable targets, such as toxins, reactions associated with organ transplants, hormone-related diseases, and non-cancerous diseased cells or tissue.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us